| abstract |
The invention provides a series of novel polyfluorinated pyrazolopyrimidine compounds or salts. Such compounds are inhibitors of tyrosine kinases (BTK). Such compounds may have better kinase inhibitory selectivity and pharmacokinetic properties. The invention discloses a preparation method of the compound. The present invention also discloses a combined drug comprising the compound and other targeted drug compositions or other drugs. The optimized drug combination has a synergistic effect, can inhibit tumor survival better than a single targeted drug, and can cause some tumors to disappear completely. The optimized drug combination can better treat tumor drug resistance and cancer recurrence than a single targeted drug, and the treatment cycle is shorter. The present invention also relates to combination compounds and their pharmaceutical preparations as active ingredients, which are safer and have synergistic curative effects at lower doses. The invention also includes methods of using these compounds and their formulations to treat and inhibit autoimmune diseases or disorders, heteroimmune diseases or disorders, inflammatory diseases, and cancers or disorders. |